Clinical Effects of Oral Naproxen for the Treatment of Eosinophilic Pustular Folliculitis.
- Author:
Je Ho YEON
1
;
Sang Woong YOUN
;
Kyu Han KIM
;
Kwang Hyun CHO
Author Information
1. Department of Dermatology, Seoul National University College of Medicine, Seoul, Koera. khcho@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Eosinophilic pustular folliculitis;
Naproxen
- MeSH:
Consensus;
Dapsone;
Dyspepsia;
Eosinophilia;
Eosinophils;
Folliculitis;
Humans;
Indomethacin;
Naproxen;
Retrospective Studies;
Skin Diseases, Vesiculobullous;
Steroids
- From:Korean Journal of Dermatology
2008;46(12):1609-1614
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Eosinophilic pustular folliculitis (EPF) is characterized by erythematous patches of follicular papules and pustules that mainly involve the face. Although various treatments have been attempted for EPF, including systemic and topical steroids, dapsone and indomethacin, there is no consensus on the first choice for treatment. OBJECTIVE: The purpose of this study was to evaluate the clinical efficacy and safety of naproxen treatment for EPF patients. METHODS: We retrospectively reviewed the clinical records of 16 biopsy-proven EPF patients who were treated with naproxen. Initial dose of oral naproxen was 500 mg to 1,000 mg. Therapeutic effects were evaluated by 3 grades: NR (no response), PR (partial remission, >50% improvement), CR (complete remission). RESULTS: Of the 16 EPF patients, 11 patients (69%) showed either complete remission (50%) or partial remission (19%). The median time to response for good responders (CR+PR) was 1.5 weeks. Two patients (13%) had mild gastrointestinal side effects, such as indigestion, but the symptoms disappeared soon after use of a gastrointestinal protectant. CONCLUSION: Oral naproxen may be an effective and safe treatment modality for EPF.
